Lilly Ventures is an Indiana-based venture capital firm that provides investment to companies in the life sciences sector.
Business Model:
Revenue: $43.1M
Employees: 51-200
Address: 115 W Washington St
City: Indianapolis
State: IN
Zip: 46204
Country: US
Lilly Ventures is the venture capital arm of Eli Lilly and Company responsible for life science investing in North America and Europe. Its primary goal is to facilitate the success of companies in its areas of focus through early to expansion stage investments and value-adding resources. Lilly Ventures currently has $200 million under management and focuses on three major areas of interest. It partner actively with the management teams of its portfolio companies to realize the potential of their technologies.
Contact Phone:
+13174290140
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
9/2012 | FORMA Therapeutics | Series C | 10M |
12/2015 | Symic Biomedical | Series A | 0 |
12/2011 | Cerulean Pharma | Series D | 15M |
4/2004 | MedManage Systems | Series C | 6M |
1/2007 | Cylene Pharmaceuticals | Series C | 44M |
12/2009 | FORMA Therapeutics | Series B | 25.5M |
1/2006 | Avid Radiopharmaceuticals | Series A | 0 |
10/2017 | Kymera Therapeutics | Series A | 30M |
1/2013 | Aileron Therapeutics | Series D | 12M |
5/2014 | Coherus Biosciences | Series C | 54.7M |
9/2010 | Cylene Pharmaceuticals | Series D | 12M |
11/2013 | Aileron Therapeutics | Series E | 30M |
11/2002 | NexCura | Series C | 4M |
11/2009 | Receptos | Series A | 25M |
9/2004 | Remon Medical Technologies | Series C | 16M |
7/2009 | Viamet Pharmaceuticals | Series B | 25M |
10/2014 | Viamet Pharma | Series D | 60M |
6/2011 | Nimbus Therapeutics | Series A | 24M |
11/2007 | Viracta Therapeutics | Series A | 20M |
2/2006 | InnoCentive | Series A | 9M |
4/2010 | Viracta Therapeutics | Series B | 12M |
5/2007 | Avid Radiopharmaceuticals | Series C | 0 |
6/2013 | Protagonist Therapeutics | Series B | 0 |
3/2012 | Viracta Therapeutics | Series B | 0 |
5/2012 | Sutro Biopharma | Series C | 16.5M |
7/2018 | Sutro Biopharma | Series E | 0 |
2/2014 | Aeglea BioTherapeutics | Series A | 0 |
12/2005 | GlobeImmune | Series B | 34.3M |
6/2020 | Evox Therapeutics | Convertible Note | 10M |
3/2012 | Receptos | Venture Round | 30M |
11/2018 | Kymera Therapeutics | Series B | 65M |
3/2015 | Aeglea BioTherapeutics | Series B | 44M |
11/2010 | Sutro Biopharma | Series C | 36.5M |
10/2021 | IpiNovyx Bio | Seed Round | 0 |
1/2017 | Cavion | Series A | 0 |
6/2007 | Serenex | Series D | 0 |
1/2015 | Symic Biomedical | Series A | 15M |
10/2005 | Serenex | Series C | 30M |
9/2002 | Serenex | Series B | 15M |
5/2005 | Bayhill Therapeutics | Series B | 35.4M |
11/2010 | Cerulean Pharma | Series C | 24M |
1/2015 | Surface Oncology | Series A | 35M |
6/2014 | Numerate | Series C | 8.2M |
2/2015 | Lysosomal Therapeutics | Series A | 20M |
9/2003 | Conforma Therapeutics | Series C | 30M |
5/2014 | Lysosomal Therapeutics | Seed Round | 4.8M |
6/2009 | Aileron Therapeutics | Series D | 40M |
1/2009 | Intradigm Corporation | Series B | 0 |
6/2003 | Nanostream Inc. | Series C | 22M |
1/2012 | Coherus Biosciences | Series B | 0 |
3/2008 | Hydra Biosciences | Series C | 34M |
11/2009 | Trinity Biosystems | Debt Financing | 7.5M |
10/2014 | Aileron Therapeutics | Series E | 33M |
12/2009 | FORMA Therapeutics | Series B | 3M |
7/2015 | Protagonist Therapeutics | Series C | 0 |
6/2018 | Nimbus Therapeutics | Series B | 65M |
1/2009 | Hydra Biosciences | Series D | 22M |
5/2009 | Avid Radiopharmaceuticals | Series D | 0 |
1/2004 | CGI Pharmaceuticals | Series C | 22.3M |
3/2013 | Receptos | Series B | 30M |
1/2005 | Remon Medical Technologies | Series C | 0 |
12/2012 | Cerulean Pharma | Private Equity Round | 13M |
1/2004 | Hydra Biosciences | Series B | 0 |
4/2006 | Bayhill Therapeutics | Venture Round | 15.8M |
8/2006 | Cabrellis Pharmaceuticals | Series A | 27.5M |
4/2006 | MedManage Systems | Series D | 10.8M |
3/2015 | Nimbus Therapeutics | Series B | 43M |
9/2006 | Protagonist Therapeutics | Series A | 9M |
1/2007 | Standard BioTools | Series E | 0 |
8/2007 | MedManage Systems | Series E | 5M |
10/2021 | IpiNovyx Bio | Seed Round | 0 |
6/2020 | Evox Therapeutics | Convertible Note | 0 |
11/2018 | Kymera Therapeutics | Series B | 0 |
7/2018 | Sutro Biopharma | Series E | 0 |
6/2018 | Nimbus Therapeutics | Series C | 0 |
10/2017 | Kymera Therapeutics | Series A | 0 |
1/2017 | Cavion | Series A | 0 |
12/2015 | Symic Biomedical | Series A | 0 |
7/2015 | Protagonist Therapeutics | Series C | 0 |
3/2015 | Aeglea BioTherapeutics | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|